A feasibility and pilot randomized trial of a nurse-led iSupport-Taiwan program for family caregivers of people with dementia in Taiwan
Archives of Gerontology and Geriatrics Plus · 2026-12 · 3 (4) · 100340
DOI: 10.1016/j.aggp.2026.100340 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Archives of Gerontology and Geriatrics Plus, 2026-12. Verfasst von Chia-Chi Chang und 8 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government Department of Foreign Affairs and Trade, Flinders University, National Science and Technology Council.
Themen: Pflegende Angehörige, Demenz
Abstract (Originalsprache)
Aims
To evaluate the feasibility, acceptability, and preliminary clinical trends of a nurse-led digital iSupport-Taiwan program for family caregivers of people with dementia, providing foundational data to guide a future definitive randomized controlled trial (RCT).
Design
A single-site feasibility trial conducted in Taipei, Taiwan (recruitment: November 2021 – February 2022), adhering to the CONSORT 2010 extension for pilot and feasibility trials.
Methods
Family caregivers were randomized into intervention (iSupport-Taiwan) and control (usual care) groups. The six-month intervention combined self-paced online modules, virtual peer support, and nurse facilitation. Primary outcomes were feasibility metrics (recruitment rate, retention, module adherence, and user satisfaction). Secondary exploratory clinical outcomes included caregiver self-efficacy, quality of life (SF-12), social support, and care-recipient quality of life, evaluated at baseline, 6 months, and 9 months.
Results
Forty-one caregivers were randomized (20 intervention, 21 control; 102.5% recruitment target achievement). Two control participants withdrew prior to study commencement. Retention among commenced participants was 100% (39/39; 95.1% overall). Module completion adherence reached 85.0% (17/20), and mean satisfaction was 4.3/5. Higher SF-12 physical health scores in the intervention group reflected baseline group non-equivalence rather than a treatment effect, as both groups exhibited a downward trajectory over 9 months.
Conclusion
The culturally adapted iSupport-Taiwan program demonstrated high feasibility and acceptability. Exploratory clinical findings do not establish treatment efficacy or physical health improvement, underscoring the necessity of pre-specified baseline-adjusted analytical frameworks (ANCOVA) and attention-matched control conditions in future definitive RCTs.
Trial registration
The main trial of this study is registered in the Australia New Zealand Clinical Trials Registry on 12th March 2021 (ACTRN12621000276853).
Förderung
- Australian Government Department of Foreign Affairs and Trade
- Flinders University
- National Science and Technology Council
Zitieren
APA
Chang, C., Hong, J., Eka, N. G. A., Tahulending, P. S., Liu, M. F., Hu, C., Xiao, L., Pakpahan, M., & Chang, H. R. (2026). A feasibility and pilot randomized trial of a nurse-led iSupport-Taiwan program for family caregivers of people with dementia in Taiwan. Archives of Gerontology and Geriatrics Plus, 3(4), 100340. https://doi.org/10.1016/j.aggp.2026.100340
Vancouver
Chang C, Hong J, Eka NGA, Tahulending PS, Liu MF, Hu C, et al. A feasibility and pilot randomized trial of a nurse-led iSupport-Taiwan program for family caregivers of people with dementia in Taiwan. Archives of Gerontology and Geriatrics Plus. 2026;3(4):100340. doi:10.1016/j.aggp.2026.100340
BibTeX
@article{Chang2026,
author = {Chang, Chia-Chi and Hong, Jhih-yang and Eka, Ni Gusti Ayu and Tahulending, Peggy Sara and Liu, Megan F. and Hu, Chaur-jong and Xiao, Lily and Pakpahan, Martina and Chang, Hui-Chen (Rita)},
title = {A feasibility and pilot randomized trial of a nurse-led iSupport-Taiwan program for family caregivers of people with dementia in Taiwan},
journal = {Archives of Gerontology and Geriatrics Plus},
year = {2026},
volume = {3},
number = {4},
pages = {100340},
doi = {10.1016/j.aggp.2026.100340}
}
EUVIMED